Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.

doi:10.1016/j.ejca.2017.10.014

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.

European journal of cancer (Oxford, England : 1990) - 1 Dec 2017

Schöffski Patrick, Wozniak Agnieszka, Escudier Bernard, Rutkowski Piotr, Anthoney Alan, Bauer Sebastian, Sufliarsky Jozef, van Herpen Carla, Lindner Lars H, Grünwald Viktor, Zakotnik Branko, Lerut Evelyne, Debiec-Rychter Maria, Marréaud Sandrine, Lia Michela, Raveloarivahy Tiana, Collette Sandra, Albiges Laurence

Abstract excerpt

PURPOSE: Papillary renal-cell carcinoma type 1 (PRCC1) is associated with MET gene alterations. Our phase II trial prospectively assessed the efficacy and safety of crizotinib in patients with advanced/metastatic PRCC1 with or without MET mutations (MET+ and MET-). EXPERIMENTAL DESIGN: Eligible patients with reference pathology-confirmed PRCC1 received 250 mg oral crizotinib twice daily. Patients were attributed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crizotinib

Share to Disease-Free Survival

Share to Gene Amplification

Share to Kidney Neoplasms

Share to Proto-Oncogene Proteins c-met

Share to Pyrazoles

Share to Pyridines

Source

Open in PubMed

Identifiers

PMID: 29149761
DOI: 10.1016/j.ejca.2017.10.014

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.PMID 29149761Read ↗

Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.Semantic proximity Read ↗

Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study.Semantic proximity Read ↗

MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array.Semantic proximity Read ↗

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.Semantic proximity Read ↗

Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic.Semantic proximity Read ↗

Combining VEGFR tyrosine kinase inhibitors and PD-1/PD-L1 inhibitors versus VEGFR tyrosine kinase inhibitors monotherapy in renal cell carcinoma: a target trial emulationSemantic proximity Read ↗

Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.Semantic proximity Read ↗

Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.Semantic proximity Read ↗

Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancersSemantic proximity Read ↗

Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.Semantic proximity Read ↗

CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer.Semantic proximity Read ↗

MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.